Trial Outcomes & Findings for A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes (NCT NCT03846453)

NCT ID: NCT03846453

Last Updated: 2022-04-14

Results Overview

It was evaluated for the inferior region on the Ora Calibra® and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

637 participants

Primary outcome timeframe

Pre-CAE and Post-CAE on Day 1 (Baseline) and Day 57

Results posted on

2022-04-14

Participant Flow

Participants who met all the eligibility criteria were enrolled at 12 sites in the United States.

A total of 1108 patients were screened and 637 patients were enrolled and randomized to one of the treatment groups. The enrollment number in Protocol refers to the participants randomized to the treatment group.

Participant milestones

Participant milestones
Measure
Placebo-Run in Participants
All participants entered placebo-run in period for 14 days prior to randomization. During the period, exposures to the CAE were conducted to ascertain eligibility to enter the study. Those who qualified were randomized to either 0.25% HL036 Ophthalmic Solution group or placebo group.
0.25% HL036 Ophthalmic Solution
Participants self-administered HL036 0.25 % ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment (CAE®) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
Participants self-administered HL036 placebo (vehicle solution) as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo Run-in (14 Days)
STARTED
1108
0
0
Placebo Run-in (14 Days)
COMPLETED
637
0
0
Placebo Run-in (14 Days)
NOT COMPLETED
471
0
0
Randomized Treatment Period (Days 57±3)
STARTED
0
318
319
Randomized Treatment Period (Days 57±3)
COMPLETED
0
291
294
Randomized Treatment Period (Days 57±3)
NOT COMPLETED
0
27
25

Reasons for withdrawal

Reasons for withdrawal
Measure
Placebo-Run in Participants
All participants entered placebo-run in period for 14 days prior to randomization. During the period, exposures to the CAE were conducted to ascertain eligibility to enter the study. Those who qualified were randomized to either 0.25% HL036 Ophthalmic Solution group or placebo group.
0.25% HL036 Ophthalmic Solution
Participants self-administered HL036 0.25 % ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment (CAE®) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
Participants self-administered HL036 placebo (vehicle solution) as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo Run-in (14 Days)
Eligibility Criteria Not Met
465
0
0
Placebo Run-in (14 Days)
Withdrawal by Subject
3
0
0
Placebo Run-in (14 Days)
Physician Decision
1
0
0
Placebo Run-in (14 Days)
Other
2
0
0
Randomized Treatment Period (Days 57±3)
Adverse Event
0
16
8
Randomized Treatment Period (Days 57±3)
Protocol Violation
0
6
5
Randomized Treatment Period (Days 57±3)
Administrative Reasons
0
2
4
Randomized Treatment Period (Days 57±3)
Withdrawal by Subject
0
2
4
Randomized Treatment Period (Days 57±3)
Other
0
1
4

Baseline Characteristics

A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Total
n=637 Participants
Total of all reporting groups
Age, Continuous
61.0 years
STANDARD_DEVIATION 12.86 • n=99 Participants
62.9 years
STANDARD_DEVIATION 14.02 • n=107 Participants
62.0 years
STANDARD_DEVIATION 13.48 • n=206 Participants
Sex: Female, Male
Female
230 Participants
n=99 Participants
211 Participants
n=107 Participants
441 Participants
n=206 Participants
Sex: Female, Male
Male
88 Participants
n=99 Participants
108 Participants
n=107 Participants
196 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
24 Participants
n=99 Participants
25 Participants
n=107 Participants
49 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
294 Participants
n=99 Participants
294 Participants
n=107 Participants
588 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
2 Participants
n=107 Participants
2 Participants
n=206 Participants
Race (NIH/OMB)
Asian
18 Participants
n=99 Participants
19 Participants
n=107 Participants
37 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
71 Participants
n=99 Participants
53 Participants
n=107 Participants
124 Participants
n=206 Participants
Race (NIH/OMB)
White
228 Participants
n=99 Participants
238 Participants
n=107 Participants
466 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
1 Participants
n=99 Participants
7 Participants
n=107 Participants
8 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants

PRIMARY outcome

Timeframe: Pre-CAE and Post-CAE on Day 1 (Baseline) and Day 57

Population: ITT Population with the Markov Chain Monte Carlo (MCMC) imputation method for missing values.

It was evaluated for the inferior region on the Ora Calibra® and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Coprimary Endpoint: Change From Baseline in Inferior Corneal Fluorescein Staining Score to Day 57 (Pre- to Post-CAE)
Day 1 (Change from Pre-CAE to Post-CAE)
1.38 score on a scale
Standard Deviation 0.427
1.31 score on a scale
Standard Deviation 0.411
Coprimary Endpoint: Change From Baseline in Inferior Corneal Fluorescein Staining Score to Day 57 (Pre- to Post-CAE)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.47 score on a scale
Standard Deviation 0.900
-0.52 score on a scale
Standard Deviation 0.762

PRIMARY outcome

Timeframe: Baseline (Day 1 Pre-CAE), Day 57 (Pre-CAE)

Population: ITT Population with the MCMC imputation method for missing values.

It is assessed by the Ora Calibra® Ocular Discomfort scale. The score ranged from 0 to 4 (0=none and 4=severe) with 1 point increments, where lower scores indicate improvement.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Coprimary Endpoint: Change From Baseline in Ocular Discomfort Score to Day 57 (Pre-CAE)
Day 1 Pre-CAE
2.61 score on a scale
Standard Deviation 0.975
2.53 score on a scale
Standard Deviation 1.060
Coprimary Endpoint: Change From Baseline in Ocular Discomfort Score to Day 57 (Pre-CAE)
Change from Baseline: Day 57 (Pre-CAE)
-0.47 score on a scale
Standard Deviation 1.318
-0.47 score on a scale
Standard Deviation 1.287

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the inferior region on the Ora Calibra® and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Day 1 Pre-CAE
1.78 score on a scale
Standard Deviation 0.550
1.84 score on a scale
Standard Deviation 0.527
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Day 1 Post-CAE
3.17 score on a scale
Standard Deviation 0.548
3.15 score on a scale
Standard Deviation 0.546
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Day 1 (Change from Pre-CAE to Post-CAE)
1.38 score on a scale
Standard Deviation 0.427
1.31 score on a scale
Standard Deviation 0.411
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from Baseline: Day 8
0.08 score on a scale
Standard Deviation 0.626
-0.02 score on a scale
Standard Deviation 0.637
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.08 score on a scale
Standard Deviation 0.730
-0.14 score on a scale
Standard Deviation 0.648
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from Baseline: Day 15 (Post-CAE)
-0.54 score on a scale
Standard Deviation 0.797
-0.58 score on a scale
Standard Deviation 0.703
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.46 score on a scale
Standard Deviation 0.843
-0.44 score on a scale
Standard Deviation 0.746
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.14 score on a scale
Standard Deviation 0.651
-0.19 score on a scale
Standard Deviation 0.741
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from Baseline: Day 29 (Post-CAE)
-0.60 score on a scale
Standard Deviation 0.851
-0.69 score on a scale
Standard Deviation 0.771
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.48 score on a scale
Standard Deviation 0.840
-0.49 score on a scale
Standard Deviation 0.795
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.13 score on a scale
Standard Deviation 0.734
-0.12 score on a scale
Standard Deviation 0.713
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from Baseline: Day 57 (Post-CAE)
-0.60 score on a scale
Standard Deviation 0.855
-0.65 score on a scale
Standard Deviation 0.734
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.47 score on a scale
Standard Deviation 0.829
-0.53 score on a scale
Standard Deviation 0.709

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the superior region on the Ora Calibra® and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Day 1 Pre-CAE
1.81 score on a scale
Standard Deviation 0.617
1.82 score on a scale
Standard Deviation 0.556
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Day 1 Post-CAE
2.19 score on a scale
Standard Deviation 0.614
2.20 score on a scale
Standard Deviation 0.638
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.39 score on a scale
Standard Deviation 0.629
0.39 score on a scale
Standard Deviation 0.625
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from Baseline: Day 8
-0.10 score on a scale
Standard Deviation 0.665
-0.15 score on a scale
Standard Deviation 0.639
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.24 score on a scale
Standard Deviation 0.665
-0.26 score on a scale
Standard Deviation 0.616
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from Baseline: Day 15 (Post-CAE)
-0.31 score on a scale
Standard Deviation 0.732
-0.35 score on a scale
Standard Deviation 0.735
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.08 score on a scale
Standard Deviation 0.800
-0.09 score on a scale
Standard Deviation 0.836
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.35 score on a scale
Standard Deviation 0.652
-0.36 score on a scale
Standard Deviation 0.677
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from Baseline: Day 29 (Post-CAE)
-0.44 score on a scale
Standard Deviation 0.774
-0.41 score on a scale
Standard Deviation 0.681
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.09 score on a scale
Standard Deviation 0.887
-0.05 score on a scale
Standard Deviation 0.738
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.36 score on a scale
Standard Deviation 0.677
-0.26 score on a scale
Standard Deviation 0.672
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from Baseline: Day 57 (Post-CAE)
-0.35 score on a scale
Standard Deviation 0.779
-0.37 score on a scale
Standard Deviation 0.710
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.01 score on a scale
Standard Deviation 0.880
-0.11 score on a scale
Standard Deviation 0.902

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the central region on the Ora Calibra® and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Fluorescein Staining (Central Region)
Day 1 Pre-CAE
1.40 score on a scale
Standard Deviation 0.780
1.36 score on a scale
Standard Deviation 0.654
Mean Change From Baseline in Fluorescein Staining (Central Region)
Day 1 Post-CAE
1.63 score on a scale
Standard Deviation 0.779
1.66 score on a scale
Standard Deviation 0.721
Mean Change From Baseline in Fluorescein Staining (Central Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.22 score on a scale
Standard Deviation 0.674
0.30 score on a scale
Standard Deviation 0.552
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from Baseline: Day 8
-0.14 score on a scale
Standard Deviation 0.726
-0.02 score on a scale
Standard Deviation 0.746
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.24 score on a scale
Standard Deviation 0.748
-0.17 score on a scale
Standard Deviation 0.694
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from Baseline: Day 15 (Post-CAE)
-0.23 score on a scale
Standard Deviation 0.770
-0.24 score on a scale
Standard Deviation 0.742
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.00 score on a scale
Standard Deviation 0.818
-0.08 score on a scale
Standard Deviation 0.757
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.38 score on a scale
Standard Deviation 0.785
-0.23 score on a scale
Standard Deviation 0.737
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from Baseline: Day 29 (Post-CAE)
-0.38 score on a scale
Standard Deviation 0.718
-0.38 score on a scale
Standard Deviation 0.643
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.01 score on a scale
Standard Deviation 0.892
-0.14 score on a scale
Standard Deviation 0.753
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.32 score on a scale
Standard Deviation 0.834
-0.18 score on a scale
Standard Deviation 0.758
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from Baseline: Day 57 (Post-CAE)
-0.25 score on a scale
Standard Deviation 0.770
-0.29 score on a scale
Standard Deviation 0.687
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.07 score on a scale
Standard Deviation 0.944
-0.10 score on a scale
Standard Deviation 0.867

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the temporal region on the Ora Calibra® and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Day 1 Pre-CAE
1.62 score on a scale
Standard Deviation 0.701
1.67 score on a scale
Standard Deviation 0.738
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Day 1 Post-CAE
1.94 score on a scale
Standard Deviation 0.692
1.95 score on a scale
Standard Deviation 0.704
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.33 score on a scale
Standard Deviation 0.636
0.28 score on a scale
Standard Deviation 0.600
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from Baseline: Day 8
-0.06 score on a scale
Standard Deviation 0.714
-0.07 score on a scale
Standard Deviation 0.683
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.18 score on a scale
Standard Deviation 0.760
-0.20 score on a scale
Standard Deviation 0.726
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from Baseline: Day 15 (Post-CAE)
-0.25 score on a scale
Standard Deviation 0.705
-0.24 score on a scale
Standard Deviation 0.715
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.06 score on a scale
Standard Deviation 0.840
-0.05 score on a scale
Standard Deviation 0.801
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.12 score on a scale
Standard Deviation 0.700
-0.11 score on a scale
Standard Deviation 0.756
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from Baseline: Day 29 (Post-CAE)
-0.22 score on a scale
Standard Deviation 0.691
-0.17 score on a scale
Standard Deviation 0.691
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.10 score on a scale
Standard Deviation 0.852
-0.07 score on a scale
Standard Deviation 0.818
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.10 score on a scale
Standard Deviation 0.775
-0.11 score on a scale
Standard Deviation 0.715
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from Baseline: Day 57 (Post-CAE)
-0.11 score on a scale
Standard Deviation 0.730
-0.18 score on a scale
Standard Deviation 0.698
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.01 score on a scale
Standard Deviation 0.907
-0.07 score on a scale
Standard Deviation 0.838

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the nasal region on the Ora Calibra® and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Day 1 Pre-CAE
1.71 score on a scale
Standard Deviation 0.740
1.73 score on a scale
Standard Deviation 0.756
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Day 1 Post-CAE
2.10 score on a scale
Standard Deviation 0.760
2.08 score on a scale
Standard Deviation 0.813
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.39 score on a scale
Standard Deviation 0.666
0.35 score on a scale
Standard Deviation 0.663
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from Baseline: Day 8
-0.04 score on a scale
Standard Deviation 0.665
-0.03 score on a scale
Standard Deviation 0.673
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.13 score on a scale
Standard Deviation 0.748
-0.14 score on a scale
Standard Deviation 0.690
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from Baseline: Day 15 (Post-CAE)
-0.20 score on a scale
Standard Deviation 0.820
-0.18 score on a scale
Standard Deviation 0.797
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.07 score on a scale
Standard Deviation 0.861
-0.04 score on a scale
Standard Deviation 0.883
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.11 score on a scale
Standard Deviation 0.714
-0.14 score on a scale
Standard Deviation 0.733
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from Baseline: Day 29 (Post-CAE)
-0.23 score on a scale
Standard Deviation 0.779
-0.17 score on a scale
Standard Deviation 0.787
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.12 score on a scale
Standard Deviation 0.896
-0.03 score on a scale
Standard Deviation 0.837
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.11 score on a scale
Standard Deviation 0.743
-0.08 score on a scale
Standard Deviation 0.706
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from Baseline: Day 57 (Post-CAE)
-0.16 score on a scale
Standard Deviation 0.837
-0.15 score on a scale
Standard Deviation 0.760
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.06 score on a scale
Standard Deviation 0.891
-0.06 score on a scale
Standard Deviation 0.886

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Corneal sum score is the sum of all regions of the cornea (inferior, superior and central regions). Individual region score was evaluated on the Ora Calibra® and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Corneal sum score ranges from 0 to 12. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Day 1 Pre-CAE
4.99 score on a scale
Standard Deviation 1.266
5.01 score on a scale
Standard Deviation 1.123
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Day 1 Post-CAE
6.99 score on a scale
Standard Deviation 1.369
7.01 score on a scale
Standard Deviation 1.359
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Day 1 (Change from Pre-CAE to Post-CAE)
1.99 score on a scale
Standard Deviation 1.103
2.00 score on a scale
Standard Deviation 1.065
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from Baseline: Day 8
-0.16 score on a scale
Standard Deviation 1.406
-0.18 score on a scale
Standard Deviation 1.475
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from Baseline: Day 15 (Pre-CAE)
-0.56 score on a scale
Standard Deviation 1.505
-0.57 score on a scale
Standard Deviation 1.436
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from Baseline: Day 15 (Post-CAE)
-1.08 score on a scale
Standard Deviation 1.673
-1.17 score on a scale
Standard Deviation 1.576
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.53 score on a scale
Standard Deviation 1.646
-0.62 score on a scale
Standard Deviation 1.562
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from Baseline: Day 29 (Pre-CAE)
-0.87 score on a scale
Standard Deviation 1.475
-0.78 score on a scale
Standard Deviation 1.630
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from Baseline: Day 29 (Post-CAE)
-1.42 score on a scale
Standard Deviation 1.698
-1.47 score on a scale
Standard Deviation 1.519
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.57 score on a scale
Standard Deviation 1.737
-0.68 score on a scale
Standard Deviation 1.644
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from Baseline: Day 57 (Pre-CAE)
-0.82 score on a scale
Standard Deviation 1.664
-0.56 score on a scale
Standard Deviation 1.645
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from Baseline: Day 57 (Post-CAE)
-1.20 score on a scale
Standard Deviation 1.840
-1.31 score on a scale
Standard Deviation 1.603
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.39 score on a scale
Standard Deviation 1.853
-0.74 score on a scale
Standard Deviation 1.811

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Conjunctival sum score is the sum of all regions of the conjunctiva (temporal and nasal regions). Individual region score was evaluated on the Ora Calibra® and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Corneal sum score ranges from 0 to 8. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Day 1 Pre-CAE
3.33 score on a scale
Standard Deviation 1.327
3.40 score on a scale
Standard Deviation 1.363
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Day 1 Post-CAE
4.05 score on a scale
Standard Deviation 1.305
4.03 score on a scale
Standard Deviation 1.366
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Day 1 (Change from Pre-CAE to Post-CAE)
0.71 score on a scale
Standard Deviation 1.084
0.63 score on a scale
Standard Deviation 1.046
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from Baseline: Day 8
-0.10 score on a scale
Standard Deviation 1.187
-0.10 score on a scale
Standard Deviation 1.129
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from Baseline: Day 15 (Pre-CAE)
-0.31 score on a scale
Standard Deviation 1.336
-0.34 score on a scale
Standard Deviation 1.218
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from Baseline: Day 15 (Post-CAE)
-0.44 score on a scale
Standard Deviation 1.308
-0.42 score on a scale
Standard Deviation 1.340
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.13 score on a scale
Standard Deviation 1.388
-0.08 score on a scale
Standard Deviation 1.399
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from Baseline: Day 29 (Pre-CAE)
-0.23 score on a scale
Standard Deviation 1.225
-0.25 score on a scale
Standard Deviation 1.308
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from Baseline: Day 29 (Post-CAE)
-0.45 score on a scale
Standard Deviation 1.285
-0.34 score on a scale
Standard Deviation 1.215
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.22 score on a scale
Standard Deviation 1.501
-0.10 score on a scale
Standard Deviation 1.357
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from Baseline: Day 57 (Pre-CAE)
-0.22 score on a scale
Standard Deviation 1.332
-0.19 score on a scale
Standard Deviation 1.215
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from Baseline: Day 57 (Post-CAE)
-0.27 score on a scale
Standard Deviation 1.345
-0.33 score on a scale
Standard Deviation 1.280
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.07 score on a scale
Standard Deviation 1.479
-0.12 score on a scale
Standard Deviation 1.432

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Total score was sum of all 5 regions: central, superior, inferior, temporal, and nasal. Individual region score was evaluated on the Ora Calibra® and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 20. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 15 (Post-CAE)
-1.53 score on a scale
Standard Deviation 2.442
-1.59 score on a scale
Standard Deviation 2.440
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.66 score on a scale
Standard Deviation 2.393
-0.70 score on a scale
Standard Deviation 2.403
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Day 1 Pre-CAE
8.33 score on a scale
Standard Deviation 2.209
8.41 score on a scale
Standard Deviation 2.075
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Day 1 Post-CAE
11.03 score on a scale
Standard Deviation 2.164
11.04 score on a scale
Standard Deviation 2.246
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Day 1 (Change from Pre-CAE to Post-CAE)
2.71 score on a scale
Standard Deviation 1.668
2.63 score on a scale
Standard Deviation 1.703
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 8
-0.26 score on a scale
Standard Deviation 2.191
-0.29 score on a scale
Standard Deviation 2.208
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 15 (Pre-CAE)
-0.87 score on a scale
Standard Deviation 2.462
-0.91 score on a scale
Standard Deviation 2.296
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 29 (Pre-CAE)
-1.10 score on a scale
Standard Deviation 2.298
-1.02 score on a scale
Standard Deviation 2.521
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 29 (Post-CAE)
-1.87 score on a scale
Standard Deviation 2.496
-1.82 score on a scale
Standard Deviation 2.288
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.79 score on a scale
Standard Deviation 2.618
-0.78 score on a scale
Standard Deviation 2.423
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 57 (Pre-CAE)
-1.03 score on a scale
Standard Deviation 2.522
-0.75 score on a scale
Standard Deviation 2.445
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 57 (Post-CAE)
-1.48 score on a scale
Standard Deviation 2.711
-1.64 score on a scale
Standard Deviation 2.423
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.46 score on a scale
Standard Deviation 2.693
-0.86 score on a scale
Standard Deviation 2.739

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the inferior region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Lissamine Green Staining Score (Inferior Region)
Day 1 Post-CAE
1.71 score on a scale
Standard Deviation 1.084
1.72 score on a scale
Standard Deviation 1.008
Mean Change From Baseline in Lissamine Green Staining Score (Inferior Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.67 score on a scale
Standard Deviation 0.918
0.60 score on a scale
Standard Deviation 0.922
Mean Change From Baseline in Lissamine Green Staining Score (Inferior Region)
Change from Baseline: Day 8
0.03 score on a scale
Standard Deviation 0.771
-0.05 score on a scale
Standard Deviation 0.799
Mean Change From Baseline in Lissamine Green Staining Score (Inferior Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.08 score on a scale
Standard Deviation 0.723
-0.13 score on a scale
Standard Deviation 0.796
Mean Change From Baseline in Lissamine Green Staining Score (Inferior Region)
Change from Baseline: Day 15 (Post-CAE)
-0.14 score on a scale
Standard Deviation 1.035
-0.18 score on a scale
Standard Deviation 1.045
Mean Change From Baseline in Lissamine Green Staining Score (Inferior Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.05 score on a scale
Standard Deviation 1.088
-0.05 score on a scale
Standard Deviation 1.207
Mean Change From Baseline in Lissamine Green Staining Score (Inferior Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.09 score on a scale
Standard Deviation 0.725
-0.21 score on a scale
Standard Deviation 0.812
Mean Change From Baseline in Lissamine Green Staining Score (Inferior Region)
Change from Baseline: Day 29 (Post-CAE)
-0.15 score on a scale
Standard Deviation 1.071
-0.19 score on a scale
Standard Deviation 1.041
Mean Change From Baseline in Lissamine Green Staining Score (Inferior Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.07 score on a scale
Standard Deviation 1.078
0.01 score on a scale
Standard Deviation 1.169
Mean Change From Baseline in Lissamine Green Staining Score (Inferior Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.11 score on a scale
Standard Deviation 0.744
-0.21 score on a scale
Standard Deviation 0.793
Mean Change From Baseline in Lissamine Green Staining Score (Inferior Region)
Change from Baseline: Day 57 (Post-CAE)
-0.20 score on a scale
Standard Deviation 1.015
-0.25 score on a scale
Standard Deviation 0.953
Mean Change From Baseline in Lissamine Green Staining Score (Inferior Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.09 score on a scale
Standard Deviation 1.064
-0.03 score on a scale
Standard Deviation 1.142
Mean Change From Baseline in Lissamine Green Staining Score (Inferior Region)
Day 1 Pre-CAE
1.03 score on a scale
Standard Deviation 0.720
1.12 score on a scale
Standard Deviation 0.754

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the superior region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Lissamine Green Staining Score (Superior Region)
Day 1 Pre-CAE
0.81 score on a scale
Standard Deviation 0.710
0.82 score on a scale
Standard Deviation 0.695
Mean Change From Baseline in Lissamine Green Staining Score (Superior Region)
Day 1 Post-CAE
0.96 score on a scale
Standard Deviation 0.806
0.98 score on a scale
Standard Deviation 0.820
Mean Change From Baseline in Lissamine Green Staining Score (Superior Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.15 score on a scale
Standard Deviation 0.587
0.17 score on a scale
Standard Deviation 0.569
Mean Change From Baseline in Lissamine Green Staining Score (Superior Region)
Change from Baseline: Day 8
-0.04 score on a scale
Standard Deviation 0.662
-0.07 score on a scale
Standard Deviation 0.674
Mean Change From Baseline in Lissamine Green Staining Score (Superior Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.13 score on a scale
Standard Deviation 0.660
-0.13 score on a scale
Standard Deviation 0.675
Mean Change From Baseline in Lissamine Green Staining Score (Superior Region)
Change from Baseline: Day 15 (Post-CAE)
-0.15 score on a scale
Standard Deviation 0.634
-0.13 score on a scale
Standard Deviation 0.739
Mean Change From Baseline in Lissamine Green Staining Score (Superior Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.01 score on a scale
Standard Deviation 0.785
0.01 score on a scale
Standard Deviation 0.780
Mean Change From Baseline in Lissamine Green Staining Score (Superior Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.17 score on a scale
Standard Deviation 0.598
-0.18 score on a scale
Standard Deviation 0.639
Mean Change From Baseline in Lissamine Green Staining Score (Superior Region)
Change from Baseline: Day 29 (Post-CAE)
-0.17 score on a scale
Standard Deviation 0.644
-0.16 score on a scale
Standard Deviation 0.709
Mean Change From Baseline in Lissamine Green Staining Score (Superior Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
0.00 score on a scale
Standard Deviation 0.793
0.03 score on a scale
Standard Deviation 0.792
Mean Change From Baseline in Lissamine Green Staining Score (Superior Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.21 score on a scale
Standard Deviation 0.620
-0.18 score on a scale
Standard Deviation 0.606
Mean Change From Baseline in Lissamine Green Staining Score (Superior Region)
Change from Baseline: Day 57 (Post-CAE)
-0.18 score on a scale
Standard Deviation 0.605
-0.22 score on a scale
Standard Deviation 0.620
Mean Change From Baseline in Lissamine Green Staining Score (Superior Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.03 score on a scale
Standard Deviation 0.780
-0.03 score on a scale
Standard Deviation 0.805

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the central region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Lissamine Green Staining Score (Central Region)
Day 1 Pre-CAE
0.39 score on a scale
Standard Deviation 0.691
0.39 score on a scale
Standard Deviation 0.646
Mean Change From Baseline in Lissamine Green Staining Score (Central Region)
Day 1 Post-CAE
0.55 score on a scale
Standard Deviation 0.698
0.57 score on a scale
Standard Deviation 0.731
Mean Change From Baseline in Lissamine Green Staining Score (Central Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.15 score on a scale
Standard Deviation 0.587
0.18 score on a scale
Standard Deviation 0.559
Mean Change From Baseline in Lissamine Green Staining Score (Central Region)
Change from Baseline: Day 8
-0.02 score on a scale
Standard Deviation 0.662
-0.04 score on a scale
Standard Deviation 0.625
Mean Change From Baseline in Lissamine Green Staining Score (Central Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.11 score on a scale
Standard Deviation 0.620
-0.04 score on a scale
Standard Deviation 0.663
Mean Change From Baseline in Lissamine Green Staining Score (Central Region)
Change from Baseline: Day 15 (Post-CAE)
-0.08 score on a scale
Standard Deviation 0.631
-0.08 score on a scale
Standard Deviation 0.698
Mean Change From Baseline in Lissamine Green Staining Score (Central Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.02 score on a scale
Standard Deviation 0.705
-0.04 score on a scale
Standard Deviation 0.788
Mean Change From Baseline in Lissamine Green Staining Score (Central Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.11 score on a scale
Standard Deviation 0.671
-0.08 score on a scale
Standard Deviation 0.586
Mean Change From Baseline in Lissamine Green Staining Score (Central Region)
Change from Baseline: Day 29 (Post-CAE)
-0.12 score on a scale
Standard Deviation 0.554
-0.17 score on a scale
Standard Deviation 0.616
Mean Change From Baseline in Lissamine Green Staining Score (Central Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.02 score on a scale
Standard Deviation 0.784
-0.09 score on a scale
Standard Deviation 0.683
Mean Change From Baseline in Lissamine Green Staining Score (Central Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.16 score on a scale
Standard Deviation 0.650
-0.12 score on a scale
Standard Deviation 0.608
Mean Change From Baseline in Lissamine Green Staining Score (Central Region)
Change from Baseline: Day 57 (Post-CAE)
-0.17 score on a scale
Standard Deviation 0.623
-0.17 score on a scale
Standard Deviation 0.595
Mean Change From Baseline in Lissamine Green Staining Score (Central Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.01 score on a scale
Standard Deviation 0.749
-0.05 score on a scale
Standard Deviation 0.783

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the temporal region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Lissamine Green Staining Score (Temporal Region)
Day 1 Pre-CAE
1.29 score on a scale
Standard Deviation 0.734
1.35 score on a scale
Standard Deviation 0.759
Mean Change From Baseline in Lissamine Green Staining Score (Temporal Region)
Day 1 Post-CAE
1.47 score on a scale
Standard Deviation 0.798
1.55 score on a scale
Standard Deviation 0.850
Mean Change From Baseline in Lissamine Green Staining Score (Temporal Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.18 score on a scale
Standard Deviation 0.601
0.21 score on a scale
Standard Deviation 0.752
Mean Change From Baseline in Lissamine Green Staining Score (Temporal Region)
Change from Baseline: Day 8
-0.12 score on a scale
Standard Deviation 0.708
-0.07 score on a scale
Standard Deviation 0.811
Mean Change From Baseline in Lissamine Green Staining Score (Temporal Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.14 score on a scale
Standard Deviation 0.733
-0.18 score on a scale
Standard Deviation 0.806
Mean Change From Baseline in Lissamine Green Staining Score (Temporal Region)
Change from Baseline: Day 15 (Post-CAE)
-0.11 score on a scale
Standard Deviation 0.714
-0.23 score on a scale
Standard Deviation 0.715
Mean Change From Baseline in Lissamine Green Staining Score (Temporal Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.03 score on a scale
Standard Deviation 0.865
-0.07 score on a scale
Standard Deviation 0.887
Mean Change From Baseline in Lissamine Green Staining Score (Temporal Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.21 score on a scale
Standard Deviation 0.687
-0.19 score on a scale
Standard Deviation 0.827
Mean Change From Baseline in Lissamine Green Staining Score (Temporal Region)
Change from Baseline: Day 29 (Post-CAE)
-0.22 score on a scale
Standard Deviation 0.659
-0.29 score on a scale
Standard Deviation 0.780
Mean Change From Baseline in Lissamine Green Staining Score (Temporal Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.03 score on a scale
Standard Deviation 0.811
-0.09 score on a scale
Standard Deviation 0.918
Mean Change From Baseline in Lissamine Green Staining Score (Temporal Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.18 score on a scale
Standard Deviation 0.774
-0.21 score on a scale
Standard Deviation 0.817
Mean Change From Baseline in Lissamine Green Staining Score (Temporal Region)
Change from Baseline: Day 57 (Post-CAE)
-0.18 score on a scale
Standard Deviation 0.774
-0.23 score on a scale
Standard Deviation 0.822
Mean Change From Baseline in Lissamine Green Staining Score (Temporal Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.00 score on a scale
Standard Deviation 0.868
-0.02 score on a scale
Standard Deviation 1.023

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the nasal region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Lissamine Green Staining Score (Nasal Region)
Day 1 Pre-CAE
1.51 score on a scale
Standard Deviation 0.852
1.48 score on a scale
Standard Deviation 0.823
Mean Change From Baseline in Lissamine Green Staining Score (Nasal Region)
Day 1 Post-CAE
1.80 score on a scale
Standard Deviation 0.903
1.82 score on a scale
Standard Deviation 0.915
Mean Change From Baseline in Lissamine Green Staining Score (Nasal Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.29 score on a scale
Standard Deviation 0.680
0.34 score on a scale
Standard Deviation 0.697
Mean Change From Baseline in Lissamine Green Staining Score (Nasal Region)
Change from Baseline: Day 8
-0.09 score on a scale
Standard Deviation 0.732
-0.07 score on a scale
Standard Deviation 0.655
Mean Change From Baseline in Lissamine Green Staining Score (Nasal Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.16 score on a scale
Standard Deviation 0.772
-0.16 score on a scale
Standard Deviation 0.695
Mean Change From Baseline in Lissamine Green Staining Score (Nasal Region)
Change from Baseline: Day 15 (Post-CAE)
-0.14 score on a scale
Standard Deviation 0.808
-0.23 score on a scale
Standard Deviation 0.729
Mean Change From Baseline in Lissamine Green Staining Score (Nasal Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.03 score on a scale
Standard Deviation 0.894
-0.09 score on a scale
Standard Deviation 0.830
Mean Change From Baseline in Lissamine Green Staining Score (Nasal Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.24 score on a scale
Standard Deviation 0.801
-0.22 score on a scale
Standard Deviation 0.690
Mean Change From Baseline in Lissamine Green Staining Score (Nasal Region)
Change from Baseline: Day 29 (Post-CAE)
-0.28 score on a scale
Standard Deviation 0.804
-0.37 score on a scale
Standard Deviation 0.810
Mean Change From Baseline in Lissamine Green Staining Score (Nasal Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.07 score on a scale
Standard Deviation 0.896
-0.16 score on a scale
Standard Deviation 0.905
Mean Change From Baseline in Lissamine Green Staining Score (Nasal Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.17 score on a scale
Standard Deviation 0.751
-0.16 score on a scale
Standard Deviation 0.657
Mean Change From Baseline in Lissamine Green Staining Score (Nasal Region)
Change from Baseline: Day 57 (Post-CAE)
-0.20 score on a scale
Standard Deviation 0.898
-0.29 score on a scale
Standard Deviation 0.816
Mean Change From Baseline in Lissamine Green Staining Score (Nasal Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.04 score on a scale
Standard Deviation 0.985
-0.13 score on a scale
Standard Deviation 0.862

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Corneal sum score is the sum of all regions of the cornea (inferior, superior and central regions). Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 12. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Lissamine Green Staining (Corneal Sum)
Day 1 Pre-CAE
2.24 score on a scale
Standard Deviation 1.711
2.33 score on a scale
Standard Deviation 1.621
Mean Change From Baseline in Lissamine Green Staining (Corneal Sum)
Day 1 Post-CAE
3.22 score on a scale
Standard Deviation 2.083
3.27 score on a scale
Standard Deviation 2.082
Mean Change From Baseline in Lissamine Green Staining (Corneal Sum)
Day 1 (Change from Pre-CAE to Post-CAE)
0.98 score on a scale
Standard Deviation 1.522
0.95 score on a scale
Standard Deviation 1.433
Mean Change From Baseline in Lissamine Green Staining (Corneal Sum)
Change from Baseline: Day 8
-0.04 score on a scale
Standard Deviation 1.663
-0.16 score on a scale
Standard Deviation 1.644
Mean Change From Baseline in Lissamine Green Staining (Corneal Sum)
Change from Baseline: Day 15 (Pre-CAE)
-0.32 score on a scale
Standard Deviation 1.594
-0.30 score on a scale
Standard Deviation 1.599
Mean Change From Baseline in Lissamine Green Staining (Corneal Sum)
Change from Baseline: Day 15 (Post-CAE)
-0.37 score on a scale
Standard Deviation 1.696
-0.39 score on a scale
Standard Deviation 1.846
Mean Change From Baseline in Lissamine Green Staining (Corneal Sum)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.04 score on a scale
Standard Deviation 1.875
-0.08 score on a scale
Standard Deviation 1.933
Mean Change From Baseline in Lissamine Green Staining (Corneal Sum)
Change from Baseline: Day 29 (Pre-CAE)
-0.37 score on a scale
Standard Deviation 1.513
-0.47 score on a scale
Standard Deviation 1.555
Mean Change From Baseline in Lissamine Green Staining (Corneal Sum)
Change from Baseline: Day 29 (Post-CAE)
-0.44 score on a scale
Standard Deviation 1.688
-0.52 score on a scale
Standard Deviation 1.805
Mean Change From Baseline in Lissamine Green Staining (Corneal Sum)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.09 score on a scale
Standard Deviation 1.899
-0.05 score on a scale
Standard Deviation 1.884
Mean Change From Baseline in Lissamine Green Staining (Corneal Sum)
Change from Baseline: Day 57 (Pre-CAE)
-0.48 score on a scale
Standard Deviation 1.502
-0.51 score on a scale
Standard Deviation 1.473
Mean Change From Baseline in Lissamine Green Staining (Corneal Sum)
Change from Baseline: Day 57 (Post-CAE)
-0.55 score on a scale
Standard Deviation 1.676
-0.63 score on a scale
Standard Deviation 1.609
Mean Change From Baseline in Lissamine Green Staining (Corneal Sum)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.06 score on a scale
Standard Deviation 1.833
-0.12 score on a scale
Standard Deviation 1.900

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Conjunctival sum score is the sum of all regions of the conjunctiva (temporal and nasal regions). Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 8. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Lissamine Green Staining (Conjunctival Sum)
Day 1 Pre-CAE
2.81 score on a scale
Standard Deviation 1.428
2.83 score on a scale
Standard Deviation 1.436
Mean Change From Baseline in Lissamine Green Staining (Conjunctival Sum)
Day 1 Post-CAE
3.28 score on a scale
Standard Deviation 1.520
3.37 score on a scale
Standard Deviation 1.551
Mean Change From Baseline in Lissamine Green Staining (Conjunctival Sum)
Day 1 (Change from Pre-CAE to Post-CAE)
0.47 score on a scale
Standard Deviation 1.080
0.54 score on a scale
Standard Deviation 1.181
Mean Change From Baseline in Lissamine Green Staining (Conjunctival Sum)
Change from Baseline: Day 8
-0.21 score on a scale
Standard Deviation 1.235
-0.15 score on a scale
Standard Deviation 1.241
Mean Change From Baseline in Lissamine Green Staining (Conjunctival Sum)
Change from Baseline: Day 15 (Pre-CAE)
-0.30 score on a scale
Standard Deviation 1.271
-0.34 score on a scale
Standard Deviation 1.335
Mean Change From Baseline in Lissamine Green Staining (Conjunctival Sum)
Change from Baseline: Day 15 (Post-CAE)
-0.25 score on a scale
Standard Deviation 1.232
-0.46 score on a scale
Standard Deviation 1.142
Mean Change From Baseline in Lissamine Green Staining (Conjunctival Sum)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.05 score on a scale
Standard Deviation 1.442
-0.16 score on a scale
Standard Deviation 1.351
Mean Change From Baseline in Lissamine Green Staining (Conjunctival Sum)
Change from Baseline: Day 29 (Pre-CAE)
-0.44 score on a scale
Standard Deviation 1.263
-0.41 score on a scale
Standard Deviation 1.269
Mean Change From Baseline in Lissamine Green Staining (Conjunctival Sum)
Change from Baseline: Day 29 (Post-CAE)
-0.51 score on a scale
Standard Deviation 1.220
-0.67 score on a scale
Standard Deviation 1.261
Mean Change From Baseline in Lissamine Green Staining (Conjunctival Sum)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.10 score on a scale
Standard Deviation 1.409
-0.25 score on a scale
Standard Deviation 1.442
Mean Change From Baseline in Lissamine Green Staining (Conjunctival Sum)
Change from Baseline: Day 57 (Pre-CAE)
-0.35 score on a scale
Standard Deviation 1.315
-0.38 score on a scale
Standard Deviation 1.245
Mean Change From Baseline in Lissamine Green Staining (Conjunctival Sum)
Change from Baseline: Day 57 (Post-CAE)
-0.38 score on a scale
Standard Deviation 1.453
-0.51 score on a scale
Standard Deviation 1.383
Mean Change From Baseline in Lissamine Green Staining (Conjunctival Sum)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.04 score on a scale
Standard Deviation 1.581
-0.14 score on a scale
Standard Deviation 1.510

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Total score was sum of all 5 regions: central, superior, inferior, temporal, and nasal. Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 20. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Day 1 Pre-CAE
5.04 score on a scale
Standard Deviation 2.765
5.15 score on a scale
Standard Deviation 2.643
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Day 1 Post-CAE
6.49 score on a scale
Standard Deviation 3.166
6.64 score on a scale
Standard Deviation 3.180
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Day 1 (Change from Pre-CAE to Post-CAE)
1.45 score on a scale
Standard Deviation 2.111
1.49 score on a scale
Standard Deviation 2.067
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 8
-0.25 score on a scale
Standard Deviation 2.445
-0.31 score on a scale
Standard Deviation 2.468
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 15 (Pre-CAE)
-0.62 score on a scale
Standard Deviation 2.435
-0.63 score on a scale
Standard Deviation 2.568
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 15 (Post-CAE)
-0.62 score on a scale
Standard Deviation 2.384
-0.85 score on a scale
Standard Deviation 2.424
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.01 score on a scale
Standard Deviation 2.624
-0.25 score on a scale
Standard Deviation 2.593
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 29 (Pre-CAE)
-0.82 score on a scale
Standard Deviation 2.302
-0.88 score on a scale
Standard Deviation 2.376
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 29 (Post-CAE)
-0.94 score on a scale
Standard Deviation 2.389
-1.19 score on a scale
Standard Deviation 2.464
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.19 score on a scale
Standard Deviation 2.695
-0.30 score on a scale
Standard Deviation 2.555
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 57 (Pre-CAE)
-0.83 score on a scale
Standard Deviation 2.366
-0.89 score on a scale
Standard Deviation 2.217
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 57 (Post-CAE)
-0.93 score on a scale
Standard Deviation 2.586
-1.15 score on a scale
Standard Deviation 2.518
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.11 score on a scale
Standard Deviation 2.812
-0.26 score on a scale
Standard Deviation 2.773

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated by the Ora Calibra® conjunctival redness scale for dry eye. The score ranges from 0 to 4 (0=none and 4=severe), where lower score indicates improvement

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Measure Title Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Day 1 Pre-CAE
1.53 score on a scale
Standard Deviation 0.588
1.55 score on a scale
Standard Deviation 0.617
Measure Title Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Day 1 Post-CAE
1.89 score on a scale
Standard Deviation 0.718
1.95 score on a scale
Standard Deviation 0.739
Measure Title Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Day 1 (Change from Pre-CAE to Post-CAE)
0.36 score on a scale
Standard Deviation 0.511
0.40 score on a scale
Standard Deviation 0.503
Measure Title Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from Baseline: Day 8
-0.13 score on a scale
Standard Deviation 0.595
-0.10 score on a scale
Standard Deviation 0.528
Measure Title Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from Baseline: Day 15 (Pre-CAE)
-0.22 score on a scale
Standard Deviation 0.650
-0.18 score on a scale
Standard Deviation 0.596
Measure Title Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from Baseline: Day 15 (Post-CAE)
-0.37 score on a scale
Standard Deviation 0.691
-0.35 score on a scale
Standard Deviation 0.706
Measure Title Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.14 score on a scale
Standard Deviation 0.630
-0.17 score on a scale
Standard Deviation 0.578
Measure Title Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from Baseline: Day 29 (Pre-CAE)
-0.15 score on a scale
Standard Deviation 0.609
-0.16 score on a scale
Standard Deviation 0.607
Measure Title Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from Baseline: Day 29 (Post-CAE)
-0.31 score on a scale
Standard Deviation 0.729
-0.36 score on a scale
Standard Deviation 0.781
Measure Title Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.17 score on a scale
Standard Deviation 0.666
-0.18 score on a scale
Standard Deviation 0.620
Measure Title Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from Baseline: Day 57 (Pre-CAE)
0.04 score on a scale
Standard Deviation 0.565
-0.05 score on a scale
Standard Deviation 0.494
Measure Title Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from Baseline: Day 57 (Post-CAE)
-0.07 score on a scale
Standard Deviation 0.579
-0.26 score on a scale
Standard Deviation 0.561
Measure Title Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.10 score on a scale
Standard Deviation 0.656
-0.21 score on a scale
Standard Deviation 0.677

SECONDARY outcome

Timeframe: Post CAE on baseline (Day 1) and Days 15, 29, and 57

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

The Schirmer test strip will be placed in the lower temporal lid margin of each eye. Participants will be instructed to close their eyes and After 5 minutes have elapsed, The length of moistened area of schirmer strip will be recorded (mm) for each eye.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Schirmer's Test
Day 1 Post-CAE
5.1 mm
Standard Deviation 2.80
4.9 mm
Standard Deviation 2.80
Change From Baseline in Schirmer's Test
Change from Baseline: Day 15 (Post-CAE)
1.2 mm
Standard Deviation 5.41
2.0 mm
Standard Deviation 5.69
Change From Baseline in Schirmer's Test
Change from Baseline: Day 29 (Post-CAE)
2.0 mm
Standard Deviation 6.14
1.2 mm
Standard Deviation 5.26
Change From Baseline in Schirmer's Test
Change from Baseline: Day 57 (Post-CAE)
3.2 mm
Standard Deviation 7.55
2.4 mm
Standard Deviation 6.12

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Sodium fluorescein solution was instilled into each eye and participants were instructed to blinked several times. The time it takes to form micelles from the time that the eye is opened was noted.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Tear Film Break-Up Time
Day 1 Pre-CAE
2.482 seconds
Standard Deviation 0.8960
2.588 seconds
Standard Deviation 1.0003
Change From Baseline in Tear Film Break-Up Time
Day 1 Post-CAE
2.444 seconds
Standard Deviation 0.8056
2.504 seconds
Standard Deviation 0.9018
Change From Baseline in Tear Film Break-Up Time
Day 1 (Change from Pre-CAE to Post-CAE)
-0.037 seconds
Standard Deviation 0.7530
-0.084 seconds
Standard Deviation 0.8608
Change From Baseline in Tear Film Break-Up Time
Change from Baseline: Day 8
0.175 seconds
Standard Deviation 1.2459
0.190 seconds
Standard Deviation 1.1859
Change From Baseline in Tear Film Break-Up Time
Change from Baseline: Day 15 (Pre-CAE)
0.276 seconds
Standard Deviation 1.4305
0.368 seconds
Standard Deviation 1.3630
Change From Baseline in Tear Film Break-Up Time
Change from Baseline: Day 15 (Post-CAE)
0.340 seconds
Standard Deviation 1.4089
0.348 seconds
Standard Deviation 1.2850
Change From Baseline in Tear Film Break-Up Time
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.058 seconds
Standard Deviation 1.2997
-0.021 seconds
Standard Deviation 1.2701
Change From Baseline in Tear Film Break-Up Time
Change from Baseline: Day 29 (Pre-CAE)
0.311 seconds
Standard Deviation 1.3669
0.352 seconds
Standard Deviation 1.5754
Change From Baseline in Tear Film Break-Up Time
Change from Baseline: Day 29 (Post-CAE)
0.222 seconds
Standard Deviation 1.1373
0.302 seconds
Standard Deviation 1.2757
Change From Baseline in Tear Film Break-Up Time
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.125 seconds
Standard Deviation 1.1118
-0.071 seconds
Standard Deviation 1.2797
Change From Baseline in Tear Film Break-Up Time
Change from Baseline: Day 57 (Pre-CAE)
0.610 seconds
Standard Deviation 1.3934
0.478 seconds
Standard Deviation 1.2693
Change From Baseline in Tear Film Break-Up Time
Change from Baseline: Day 57 (Post-CAE)
0.523 seconds
Standard Deviation 1.1321
0.726 seconds
Standard Deviation 1.6787
Change From Baseline in Tear Film Break-Up Time
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.085 seconds
Standard Deviation 1.3655
0.246 seconds
Standard Deviation 1.6429

SECONDARY outcome

Timeframe: Pre-CAE on baseline (Day 1) and Days 15, 29, and 57; Day 8

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

The OSDI is a simple 12-question survey that rates the severity of the participant's dry eye disease based on the symptoms. It is assessed on a scale of 0 to 100, with higher score representing greater disability.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Ocular Surface Disease Index (OSDI)
Day 1 Pre-CAE
39.7 score on a scale
Standard Deviation 19.68
39.2 score on a scale
Standard Deviation 19.33
Change From Baseline in Ocular Surface Disease Index (OSDI)
Change from Baseline: Day 8
-2.0 score on a scale
Standard Deviation 12.50
-1.5 score on a scale
Standard Deviation 12.46
Change From Baseline in Ocular Surface Disease Index (OSDI)
Change from Baseline: Day 15 (Pre-CAE)
-2.7 score on a scale
Standard Deviation 12.07
-1.5 score on a scale
Standard Deviation 12.81
Change From Baseline in Ocular Surface Disease Index (OSDI)
Change from Baseline: Day 29 (Pre-CAE)
-3.7 score on a scale
Standard Deviation 13.13
-2.2 score on a scale
Standard Deviation 13.95
Change From Baseline in Ocular Surface Disease Index (OSDI)
Change from Baseline: Day 57 (Pre-CAE)
-2.9 score on a scale
Standard Deviation 14.69
-5.3 score on a scale
Standard Deviation 13.93

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Participants rated ocular symptom of blurry vision by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Visual Analog Scale (Blurry Vision)
Day 1 Pre-CAE
37.8 mm
Standard Deviation 28.41
32.9 mm
Standard Deviation 28.67
Change From Baseline in Visual Analog Scale (Blurry Vision)
Day 1 Post-CAE
43.7 mm
Standard Deviation 29.37
40.5 mm
Standard Deviation 29.68
Change From Baseline in Visual Analog Scale (Blurry Vision)
Day 1 (Change from Pre-CAE to Post-CAE)
5.9 mm
Standard Deviation 17.70
7.6 mm
Standard Deviation 18.80
Change From Baseline in Visual Analog Scale (Blurry Vision)
Change from Baseline: Day 8
-2.4 mm
Standard Deviation 18.85
-0.8 mm
Standard Deviation 17.90
Change From Baseline in Visual Analog Scale (Blurry Vision)
Change from Baseline: Day 15 (Pre-CAE)
-2.8 mm
Standard Deviation 20.85
-1.3 mm
Standard Deviation 18.59
Change From Baseline in Visual Analog Scale (Blurry Vision)
Change from Baseline: Day 15 (Post-CAE)
-3.9 mm
Standard Deviation 20.70
-3.1 mm
Standard Deviation 18.99
Change From Baseline in Visual Analog Scale (Blurry Vision)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.9 mm
Standard Deviation 23.30
-2.1 mm
Standard Deviation 21.88
Change From Baseline in Visual Analog Scale (Blurry Vision)
Change from Baseline: Day 29 (Pre-CAE)
-3.9 mm
Standard Deviation 22.40
-1.3 mm
Standard Deviation 20.30
Change From Baseline in Visual Analog Scale (Blurry Vision)
Change from Baseline: Day 29 (Post-CAE)
-6.2 mm
Standard Deviation 22.30
-5.2 mm
Standard Deviation 21.84
Change From Baseline in Visual Analog Scale (Blurry Vision)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-2.3 mm
Standard Deviation 22.41
-3.9 mm
Standard Deviation 23.19
Change From Baseline in Visual Analog Scale (Blurry Vision)
Change from Baseline: Day 57 (Pre-CAE)
-6.5 mm
Standard Deviation 22.49
-5.7 mm
Standard Deviation 21.23
Change From Baseline in Visual Analog Scale (Blurry Vision)
Change from Baseline: Day 57 (Post-CAE)
-7.1 mm
Standard Deviation 24.39
-6.3 mm
Standard Deviation 24.68
Change From Baseline in Visual Analog Scale (Blurry Vision)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.3 mm
Standard Deviation 22.62
-0.2 mm
Standard Deviation 24.41

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Participants rated ocular symptom of burning/stinging by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Visual Analog Scale (Burning/Stinging)
Day 1 Pre-CAE
36.6 mm
Standard Deviation 28.19
35.6 mm
Standard Deviation 27.23
Change From Baseline in Visual Analog Scale (Burning/Stinging)
Day 1 Post-CAE
49.2 mm
Standard Deviation 31.81
47.1 mm
Standard Deviation 30.02
Change From Baseline in Visual Analog Scale (Burning/Stinging)
Day 1 (Change from Pre-CAE to Post-CAE)
12.6 mm
Standard Deviation 24.32
11.5 mm
Standard Deviation 23.00
Change From Baseline in Visual Analog Scale (Burning/Stinging)
Change from Baseline: Day 8
-3.7 mm
Standard Deviation 18.86
-3.9 mm
Standard Deviation 19.55
Change From Baseline in Visual Analog Scale (Burning/Stinging)
Change from Baseline: Day 15 (Pre-CAE)
-4.9 mm
Standard Deviation 21.12
-5.7 mm
Standard Deviation 19.94
Change From Baseline in Visual Analog Scale (Burning/Stinging)
Change from Baseline: Day 15 (Post-CAE)
-5.2 mm
Standard Deviation 23.93
-4.5 mm
Standard Deviation 23.80
Change From Baseline in Visual Analog Scale (Burning/Stinging)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.1 mm
Standard Deviation 26.13
1.5 mm
Standard Deviation 24.77
Change From Baseline in Visual Analog Scale (Burning/Stinging)
Change from Baseline: Day 29 (Pre-CAE)
-6.5 mm
Standard Deviation 24.75
-5.4 mm
Standard Deviation 18.45
Change From Baseline in Visual Analog Scale (Burning/Stinging)
Change from Baseline: Day 29 (Post-CAE)
-5.2 mm
Standard Deviation 24.73
-5.4 mm
Standard Deviation 24.50
Change From Baseline in Visual Analog Scale (Burning/Stinging)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
1.5 mm
Standard Deviation 29.65
-0.6 mm
Standard Deviation 24.52
Change From Baseline in Visual Analog Scale (Burning/Stinging)
Change from Baseline: Day 57 (Pre-CAE)
-7.6 mm
Standard Deviation 23.03
-9.1 mm
Standard Deviation 21.37
Change From Baseline in Visual Analog Scale (Burning/Stinging)
Change from Baseline: Day 57 (Post-CAE)
-6.8 mm
Standard Deviation 26.31
-7.4 mm
Standard Deviation 27.83
Change From Baseline in Visual Analog Scale (Burning/Stinging)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
1.1 mm
Standard Deviation 28.56
1.8 mm
Standard Deviation 29.03

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Participants rated ocular symptom of itching by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Visual Analog Scale (Itching)
Day 1 Pre-CAE
35.9 mm
Standard Deviation 27.26
35.6 mm
Standard Deviation 27.53
Change From Baseline in Visual Analog Scale (Itching)
Day 1 Post-CAE
42.3 mm
Standard Deviation 30.44
39.6 mm
Standard Deviation 28.83
Change From Baseline in Visual Analog Scale (Itching)
Day 1 (Change from Pre-CAE to Post-CAE)
6.5 mm
Standard Deviation 21.23
4.0 mm
Standard Deviation 19.81
Change From Baseline in Visual Analog Scale (Itching)
Change from Baseline: Day 8
-5.1 mm
Standard Deviation 20.76
-4.2 mm
Standard Deviation 19.66
Change From Baseline in Visual Analog Scale (Itching)
Change from Baseline: Day 15 (Pre-CAE)
-5.2 mm
Standard Deviation 22.62
-4.6 mm
Standard Deviation 21.02
Change From Baseline in Visual Analog Scale (Itching)
Change from Baseline: Day 15 (Post-CAE)
-7.1 mm
Standard Deviation 21.79
-3.7 mm
Standard Deviation 21.96
Change From Baseline in Visual Analog Scale (Itching)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-2.0 mm
Standard Deviation 25.24
1.0 mm
Standard Deviation 23.34
Change From Baseline in Visual Analog Scale (Itching)
Change from Baseline: Day 29 (Pre-CAE)
-8.4 mm
Standard Deviation 22.61
-5.9 mm
Standard Deviation 20.75
Change From Baseline in Visual Analog Scale (Itching)
Change from Baseline: Day 29 (Post-CAE)
-7.8 mm
Standard Deviation 24.13
-5.9 mm
Standard Deviation 22.57
Change From Baseline in Visual Analog Scale (Itching)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
0.5 mm
Standard Deviation 26.78
-0.4 mm
Standard Deviation 22.52
Change From Baseline in Visual Analog Scale (Itching)
Change from Baseline: Day 57 (Pre-CAE)
-8.0 mm
Standard Deviation 21.70
-8.3 mm
Standard Deviation 23.57
Change From Baseline in Visual Analog Scale (Itching)
Change from Baseline: Day 57 (Post-CAE)
-8.9 mm
Standard Deviation 24.09
-7.2 mm
Standard Deviation 27.69
Change From Baseline in Visual Analog Scale (Itching)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.8 mm
Standard Deviation 24.68
1.3 mm
Standard Deviation 26.04

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Participants rated ocular symptom of foreign body sensation by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Visual Analog Scale (Foreign Body Sensation)
Day 1 Pre-CAE
37.8 mm
Standard Deviation 28.96
36.6 mm
Standard Deviation 28.81
Change From Baseline in Visual Analog Scale (Foreign Body Sensation)
Day 1 Post-CAE
47.5 mm
Standard Deviation 30.70
42.9 mm
Standard Deviation 30.08
Change From Baseline in Visual Analog Scale (Foreign Body Sensation)
Day 1 (Change from Pre-CAE to Post-CAE)
9.7 mm
Standard Deviation 21.96
6.3 mm
Standard Deviation 19.33
Change From Baseline in Visual Analog Scale (Foreign Body Sensation)
Change from Baseline: Day 8
-3.9 mm
Standard Deviation 19.98
-3.6 mm
Standard Deviation 21.88
Change From Baseline in Visual Analog Scale (Foreign Body Sensation)
Change from Baseline: Day 15 (Pre-CAE)
-5.5 mm
Standard Deviation 21.35
-5.6 mm
Standard Deviation 21.37
Change From Baseline in Visual Analog Scale (Foreign Body Sensation)
Change from Baseline: Day 15 (Post-CAE)
-7.9 mm
Standard Deviation 24.27
-2.9 mm
Standard Deviation 21.23
Change From Baseline in Visual Analog Scale (Foreign Body Sensation)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-2.1 mm
Standard Deviation 25.53
2.5 mm
Standard Deviation 23.43
Change From Baseline in Visual Analog Scale (Foreign Body Sensation)
Change from Baseline: Day 29 (Pre-CAE)
-6.9 mm
Standard Deviation 24.63
-4.7 mm
Standard Deviation 22.85
Change From Baseline in Visual Analog Scale (Foreign Body Sensation)
Change from Baseline: Day 29 (Post-CAE)
-9.0 mm
Standard Deviation 26.10
-4.0 mm
Standard Deviation 22.44
Change From Baseline in Visual Analog Scale (Foreign Body Sensation)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-2.0 mm
Standard Deviation 28.75
0.6 mm
Standard Deviation 22.51
Change From Baseline in Visual Analog Scale (Foreign Body Sensation)
Change from Baseline: Day 57 (Pre-CAE)
-7.6 mm
Standard Deviation 23.30
-8.2 mm
Standard Deviation 22.70
Change From Baseline in Visual Analog Scale (Foreign Body Sensation)
Change from Baseline: Day 57 (Post-CAE)
-9.1 mm
Standard Deviation 25.32
-5.6 mm
Standard Deviation 26.82
Change From Baseline in Visual Analog Scale (Foreign Body Sensation)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.9 mm
Standard Deviation 26.40
2.9 mm
Standard Deviation 25.60

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Participants rated ocular symptom of eye dryness by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Visual Analog Scale (Eye Dryness)
Day 1 Pre-CAE
61.4 mm
Standard Deviation 24.71
59.7 mm
Standard Deviation 24.58
Change From Baseline in Visual Analog Scale (Eye Dryness)
Day 1 Post-CAE
74.4 mm
Standard Deviation 22.20
72.4 mm
Standard Deviation 21.45
Change From Baseline in Visual Analog Scale (Eye Dryness)
Day 1 (Change from Pre-CAE to Post-CAE)
13.1 mm
Standard Deviation 20.49
12.7 mm
Standard Deviation 18.58
Change From Baseline in Visual Analog Scale (Eye Dryness)
Change from Baseline: Day 8
-5.5 mm
Standard Deviation 19.57
-3.7 mm
Standard Deviation 19.20
Change From Baseline in Visual Analog Scale (Eye Dryness)
Change from Baseline: Day 15 (Pre-CAE)
-7.7 mm
Standard Deviation 21.44
-6.8 mm
Standard Deviation 19.33
Change From Baseline in Visual Analog Scale (Eye Dryness)
Change from Baseline: Day 15 (Post-CAE)
-5.4 mm
Standard Deviation 17.94
-5.0 mm
Standard Deviation 17.45
Change From Baseline in Visual Analog Scale (Eye Dryness)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
2.5 mm
Standard Deviation 23.52
1.9 mm
Standard Deviation 20.81
Change From Baseline in Visual Analog Scale (Eye Dryness)
Change from Baseline: Day 29 (Pre-CAE)
-9.8 mm
Standard Deviation 23.24
-7.4 mm
Standard Deviation 22.31
Change From Baseline in Visual Analog Scale (Eye Dryness)
Change from Baseline: Day 29 (Post-CAE)
-7.4 mm
Standard Deviation 20.28
-6.9 mm
Standard Deviation 19.91
Change From Baseline in Visual Analog Scale (Eye Dryness)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
2.6 mm
Standard Deviation 25.92
0.6 mm
Standard Deviation 21.09
Change From Baseline in Visual Analog Scale (Eye Dryness)
Change from Baseline: Day 57 (Pre-CAE)
-12.9 mm
Standard Deviation 24.74
-11.3 mm
Standard Deviation 23.01
Change From Baseline in Visual Analog Scale (Eye Dryness)
Change from Baseline: Day 57 (Post-CAE)
-10.6 mm
Standard Deviation 22.58
-10.3 mm
Standard Deviation 24.63
Change From Baseline in Visual Analog Scale (Eye Dryness)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
2.3 mm
Standard Deviation 25.84
1.2 mm
Standard Deviation 24.96

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Participants rated ocular symptom of photophobia by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Visual Analog Scale (Photophobia)
Day 1 Pre-CAE
40.4 mm
Standard Deviation 30.20
37.8 mm
Standard Deviation 30.73
Change From Baseline in Visual Analog Scale (Photophobia)
Day 1 Post-CAE
46.0 mm
Standard Deviation 31.33
43.5 mm
Standard Deviation 30.48
Change From Baseline in Visual Analog Scale (Photophobia)
Day 1 (Change from Pre-CAE to Post-CAE)
5.6 mm
Standard Deviation 19.67
5.7 mm
Standard Deviation 17.70
Change From Baseline in Visual Analog Scale (Photophobia)
Change from Baseline: Day 8
-3.2 mm
Standard Deviation 16.91
-3.6 mm
Standard Deviation 17.03
Change From Baseline in Visual Analog Scale (Photophobia)
Change from Baseline: Day 15 (Pre-CAE)
-3.4 mm
Standard Deviation 18.66
-3.6 mm
Standard Deviation 18.58
Change From Baseline in Visual Analog Scale (Photophobia)
Change from Baseline: Day 15 (Post-CAE)
-4.0 mm
Standard Deviation 21.77
-4.9 mm
Standard Deviation 22.13
Change From Baseline in Visual Analog Scale (Photophobia)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.4 mm
Standard Deviation 22.09
-1.3 mm
Standard Deviation 20.38
Change From Baseline in Visual Analog Scale (Photophobia)
Change from Baseline: Day 29 (Pre-CAE)
-6.3 mm
Standard Deviation 20.75
-4.9 mm
Standard Deviation 21.05
Change From Baseline in Visual Analog Scale (Photophobia)
Change from Baseline: Day 29 (Post-CAE)
-6.5 mm
Standard Deviation 21.85
-7.0 mm
Standard Deviation 23.42
Change From Baseline in Visual Analog Scale (Photophobia)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
0.0 mm
Standard Deviation 22.25
-2.1 mm
Standard Deviation 22.44
Change From Baseline in Visual Analog Scale (Photophobia)
Change from Baseline: Day 57 (Pre-CAE)
-7.4 mm
Standard Deviation 21.60
-7.6 mm
Standard Deviation 20.66
Change From Baseline in Visual Analog Scale (Photophobia)
Change from Baseline: Day 57 (Post-CAE)
-8.2 mm
Standard Deviation 22.51
-9.5 mm
Standard Deviation 23.72
Change From Baseline in Visual Analog Scale (Photophobia)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.4 mm
Standard Deviation 22.72
-1.9 mm
Standard Deviation 22.26

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Participants rated ocular symptom of pain by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Visual Analog Scale (Pain)
Day 1 Pre-CAE
27.7 mm
Standard Deviation 26.43
26.2 mm
Standard Deviation 25.34
Change From Baseline in Visual Analog Scale (Pain)
Day 1 Post-CAE
39.3 mm
Standard Deviation 31.31
37.0 mm
Standard Deviation 29.17
Change From Baseline in Visual Analog Scale (Pain)
Day 1 (Change from Pre-CAE to Post-CAE)
11.6 mm
Standard Deviation 22.26
10.8 mm
Standard Deviation 21.13
Change From Baseline in Visual Analog Scale (Pain)
Change from Baseline: Day 8
-3.7 mm
Standard Deviation 17.44
-2.9 mm
Standard Deviation 19.27
Change From Baseline in Visual Analog Scale (Pain)
Change from Baseline: Day 15 (Pre-CAE)
-3.5 mm
Standard Deviation 20.36
-4.0 mm
Standard Deviation 19.52
Change From Baseline in Visual Analog Scale (Pain)
Change from Baseline: Day 15 (Post-CAE)
-5.2 mm
Standard Deviation 23.17
-5.8 mm
Standard Deviation 21.95
Change From Baseline in Visual Analog Scale (Pain)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-1.3 mm
Standard Deviation 24.59
-1.9 mm
Standard Deviation 21.55
Change From Baseline in Visual Analog Scale (Pain)
Change from Baseline: Day 29 (Pre-CAE)
-5.7 mm
Standard Deviation 22.52
-5.4 mm
Standard Deviation 20.52
Change From Baseline in Visual Analog Scale (Pain)
Change from Baseline: Day 29 (Post-CAE)
-6.3 mm
Standard Deviation 22.39
-9.0 mm
Standard Deviation 23.24
Change From Baseline in Visual Analog Scale (Pain)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.6 mm
Standard Deviation 24.88
-3.6 mm
Standard Deviation 23.73
Change From Baseline in Visual Analog Scale (Pain)
Change from Baseline: Day 57 (Pre-CAE)
-5.3 mm
Standard Deviation 21.66
-7.3 mm
Standard Deviation 22.61
Change From Baseline in Visual Analog Scale (Pain)
Change from Baseline: Day 57 (Post-CAE)
-7.7 mm
Standard Deviation 25.24
-8.3 mm
Standard Deviation 25.19
Change From Baseline in Visual Analog Scale (Pain)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-1.8 mm
Standard Deviation 25.64
-0.8 mm
Standard Deviation 26.50

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It was assessed by the Ora Calibra® ocular discomfort scale. The score ranges from 0 to 4 (0=none and 4=severe), where lower score indicates improvement.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Ocular Discomfort Scale
Change from Baseline: Day 15 (Post-CAE)
-0.2 mm
Standard Deviation 0.77
-0.1 mm
Standard Deviation 0.74
Change From Baseline in Ocular Discomfort Scale
Day 1 Pre-CAE
2.6 mm
Standard Deviation 0.98
2.5 mm
Standard Deviation 1.06
Change From Baseline in Ocular Discomfort Scale
Day 1 Post-CAE
3.6 mm
Standard Deviation 0.59
3.6 mm
Standard Deviation 0.64
Change From Baseline in Ocular Discomfort Scale
Day 1 (Change from Pre-CAE to Post-CAE)
1.0 mm
Standard Deviation 1.07
1.1 mm
Standard Deviation 1.12
Change From Baseline in Ocular Discomfort Scale
Change from Baseline: Day 8
-0.3 mm
Standard Deviation 1.20
-0.2 mm
Standard Deviation 1.11
Change From Baseline in Ocular Discomfort Scale
Change from Baseline: Day 15 (Pre-CAE)
-0.5 mm
Standard Deviation 1.18
-0.3 mm
Standard Deviation 1.18
Change From Baseline in Ocular Discomfort Scale
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.3 mm
Standard Deviation 1.32
0.1 mm
Standard Deviation 1.36
Change From Baseline in Ocular Discomfort Scale
Change from Baseline: Day 29 (Pre-CAE)
-0.4 mm
Standard Deviation 1.30
-0.2 mm
Standard Deviation 1.23
Change From Baseline in Ocular Discomfort Scale
Change from Baseline: Day 29 (Post-CAE)
-0.2 mm
Standard Deviation 0.73
-0.2 mm
Standard Deviation 0.84
Change From Baseline in Ocular Discomfort Scale
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
0.2 mm
Standard Deviation 1.44
0.0 mm
Standard Deviation 1.38
Change From Baseline in Ocular Discomfort Scale
Change from Baseline: Day 57 (Pre-CAE)
-0.5 mm
Standard Deviation 1.29
-0.5 mm
Standard Deviation 1.24
Change From Baseline in Ocular Discomfort Scale
Change from Baseline: Day 57 (Post-CAE)
-0.4 mm
Standard Deviation 0.91
-0.3 mm
Standard Deviation 0.95
Change From Baseline in Ocular Discomfort Scale
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.1 mm
Standard Deviation 1.41
0.2 mm
Standard Deviation 1.37

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. At each day during the at-home dosing period, subjects will grade the severity of their dry eye syndrome symptoms in the morning and in the evening, before instilling the study drug. Participants rated the severity of overall ocular discomfort on 0 to 5 scale, where 0=none and 5=severe.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Day 1 Pre-CAE
2.8 mm
Standard Deviation 0.94
2.8 mm
Standard Deviation 1.00
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Day 1 Post-CAE
3.7 mm
Standard Deviation 0.82
3.7 mm
Standard Deviation 0.79
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Day 1 (Change from Pre-CAE to Post-CAE)
0.9 mm
Standard Deviation 0.98
0.9 mm
Standard Deviation 0.98
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from Baseline: Day 8
-0.2 mm
Standard Deviation 1.05
-0.2 mm
Standard Deviation 1.03
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from Baseline: Day 15 (Pre-CAE)
-0.4 mm
Standard Deviation 1.09
-0.3 mm
Standard Deviation 0.99
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from Baseline: Day 15 (Post-CAE)
-0.2 mm
Standard Deviation 0.95
-0.3 mm
Standard Deviation 0.82
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.2 mm
Standard Deviation 1.35
0.1 mm
Standard Deviation 1.17
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from Baseline: Day 29 (Pre-CAE)
-0.4 mm
Standard Deviation 1.14
-0.3 mm
Standard Deviation 1.20
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from Baseline: Day 29 (Post-CAE)
-0.3 mm
Standard Deviation 0.86
-0.3 mm
Standard Deviation 0.89
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
0.1 mm
Standard Deviation 1.29
0.0 mm
Standard Deviation 1.40
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from Baseline: Day 57 (Pre-CAE)
-0.4 mm
Standard Deviation 1.21
-0.5 mm
Standard Deviation 1.14
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from Baseline: Day 57 (Post-CAE)
-0.4 mm
Standard Deviation 1.01
-0.4 mm
Standard Deviation 1.04
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.1 mm
Standard Deviation 1.31
0.1 mm
Standard Deviation 1.21

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. At each day during the at-home dosing period, subjects graded the severity of their dry eye syndrome symptoms in the morning and in the evening, before instilling the study drug. Participants rated the severity of burning on 0 to 5 scale, where 0=none and 5=severe.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Day 1 Pre-CAE
1.7 mm
Standard Deviation 1.43
1.7 mm
Standard Deviation 1.38
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Day 1 Post-CAE
2.6 mm
Standard Deviation 1.56
2.6 mm
Standard Deviation 1.56
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Day 1 (Change from Pre-CAE to Post-CAE)
0.9 mm
Standard Deviation 1.34
0.9 mm
Standard Deviation 1.22
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from Baseline: Day 8
-0.1 mm
Standard Deviation 1.14
-0.2 mm
Standard Deviation 1.08
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from Baseline: Day 15 (Pre-CAE)
-0.2 mm
Standard Deviation 1.18
-0.2 mm
Standard Deviation 1.15
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from Baseline: Day 15 (Post-CAE)
-0.3 mm
Standard Deviation 1.18
-0.3 mm
Standard Deviation 1.20
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.1 mm
Standard Deviation 1.50
-0.1 mm
Standard Deviation 1.43
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from Baseline: Day 29 (Pre-CAE)
-0.3 mm
Standard Deviation 1.18
-0.2 mm
Standard Deviation 1.16
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from Baseline: Day 29 (Post-CAE)
-0.3 mm
Standard Deviation 1.26
-0.3 mm
Standard Deviation 1.25
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.1 mm
Standard Deviation 1.57
-0.2 mm
Standard Deviation 1.55
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from Baseline: Day 57 (Pre-CAE)
-0.3 mm
Standard Deviation 1.19
-0.4 mm
Standard Deviation 1.25
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from Baseline: Day 57 (Post-CAE)
-0.3 mm
Standard Deviation 1.37
-0.4 mm
Standard Deviation 1.36
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.0 mm
Standard Deviation 1.49
0.0 mm
Standard Deviation 1.61

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. At each day during the at-home dosing period, subjects graded the severity of their dry eye syndrome symptoms in the morning and in the evening, before instilling the study drug. Participants rated the severity of dryness on 0 to 5 scale, where 0=none and 5=severe.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Day 1 Pre-CAE
3.2 mm
Standard Deviation 1.05
3.2 mm
Standard Deviation 0.97
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Day 1 Post-CAE
3.9 mm
Standard Deviation 0.89
3.9 mm
Standard Deviation 0.88
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Day 1 (Change from Pre-CAE to Post-CAE)
0.8 mm
Standard Deviation 0.97
0.8 mm
Standard Deviation 0.95
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from Baseline: Day 8
-0.2 mm
Standard Deviation 0.98
-0.3 mm
Standard Deviation 1.05
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from Baseline: Day 15 (Pre-CAE)
-0.4 mm
Standard Deviation 1.01
-0.4 mm
Standard Deviation 0.99
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from Baseline: Day 15 (Post-CAE)
-0.2 mm
Standard Deviation 0.85
-0.2 mm
Standard Deviation 0.78
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.1 mm
Standard Deviation 1.20
0.1 mm
Standard Deviation 1.11
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from Baseline: Day 29 (Pre-CAE)
-0.4 mm
Standard Deviation 1.16
-0.4 mm
Standard Deviation 1.22
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from Baseline: Day 29 (Post-CAE)
-0.2 mm
Standard Deviation 0.91
-0.3 mm
Standard Deviation 0.92
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
0.2 mm
Standard Deviation 1.22
0.1 mm
Standard Deviation 1.38
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from Baseline: Day 57 (Pre-CAE)
-0.5 mm
Standard Deviation 1.22
-0.6 mm
Standard Deviation 1.18
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from Baseline: Day 57 (Post-CAE)
-0.4 mm
Standard Deviation 1.12
-0.5 mm
Standard Deviation 1.10
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.1 mm
Standard Deviation 1.34
0.1 mm
Standard Deviation 1.34

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. At each day during the at-home dosing period, subjects graded the severity of their dry eye syndrome symptoms in the morning and in the evening, before instilling the study drug. Participants rated the severity of grittiness on 0 to 5 scale, where 0=none and 5=severe.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Day 1 Pre-CAE
2.1 mm
Standard Deviation 1.42
2.1 mm
Standard Deviation 1.43
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Day 1 Post-CAE
2.7 mm
Standard Deviation 1.49
2.6 mm
Standard Deviation 1.55
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Day 1 (Change from Pre-CAE to Post-CAE)
0.6 mm
Standard Deviation 1.14
0.5 mm
Standard Deviation 1.16
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from Baseline: Day 8
-0.3 mm
Standard Deviation 1.05
-0.2 mm
Standard Deviation 1.17
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from Baseline: Day 15 (Pre-CAE)
-0.3 mm
Standard Deviation 1.12
-0.3 mm
Standard Deviation 1.07
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from Baseline: Day 15 (Post-CAE)
-0.3 mm
Standard Deviation 1.20
-0.2 mm
Standard Deviation 1.06
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.0 mm
Standard Deviation 1.43
0.1 mm
Standard Deviation 1.31
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from Baseline: Day 29 (Pre-CAE)
-0.4 mm
Standard Deviation 1.14
-0.3 mm
Standard Deviation 1.15
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from Baseline: Day 29 (Post-CAE)
-0.3 mm
Standard Deviation 1.20
-0.3 mm
Standard Deviation 1.19
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
0.1 mm
Standard Deviation 1.40
0.0 mm
Standard Deviation 1.37
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from Baseline: Day 57 (Pre-CAE)
-0.4 mm
Standard Deviation 1.15
-0.4 mm
Standard Deviation 1.20
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from Baseline: Day 57 (Post-CAE)
-0.4 mm
Standard Deviation 1.29
-0.3 mm
Standard Deviation 1.32
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.1 mm
Standard Deviation 1.37
0.1 mm
Standard Deviation 1.46

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. At each day during the at-home dosing period, subjects graded the severity of their dry eye syndrome symptoms in the morning and in the evening, before instilling the study drug. Participants rated the severity of stinging on 0 to 5 scale, where 0=none and 5=severe.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Day 1 Pre-CAE
1.6 mm
Standard Deviation 1.42
1.6 mm
Standard Deviation 1.32
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Day 1 Post-CAE
2.3 mm
Standard Deviation 1.55
2.4 mm
Standard Deviation 1.52
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Day 1 (Change from Pre-CAE to Post-CAE)
0.8 mm
Standard Deviation 1.10
0.8 mm
Standard Deviation 1.11
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from Baseline: Day 8
-0.1 mm
Standard Deviation 1.00
-0.1 mm
Standard Deviation 1.03
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from Baseline: Day 15 (Pre-CAE)
-0.2 mm
Standard Deviation 1.07
-0.3 mm
Standard Deviation 1.01
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from Baseline: Day 15 (Post-CAE)
-0.3 mm
Standard Deviation 1.15
-0.3 mm
Standard Deviation 1.17
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.1 mm
Standard Deviation 1.41
0.0 mm
Standard Deviation 1.32
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from Baseline: Day 29 (Pre-CAE)
-0.3 mm
Standard Deviation 1.16
-0.3 mm
Standard Deviation 1.05
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from Baseline: Day 29 (Post-CAE)
-0.3 mm
Standard Deviation 1.30
-0.5 mm
Standard Deviation 1.26
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
0.0 mm
Standard Deviation 1.48
-0.2 mm
Standard Deviation 1.38
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from Baseline: Day 57 (Pre-CAE)
-0.4 mm
Standard Deviation 1.23
-0.4 mm
Standard Deviation 1.09
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from Baseline: Day 57 (Post-CAE)
-0.3 mm
Standard Deviation 1.24
-0.5 mm
Standard Deviation 1.31
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.1 mm
Standard Deviation 1.38
0.0 mm
Standard Deviation 1.43

SECONDARY outcome

Timeframe: Upon instillation and 1 and 2 minutes post-instillation on Day 1

Population: The ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® drop comfort scale ranges from 0 to 10. A score of 0 indicates comfortable and 10 indicates uncomfortable. Lower score indicated better comfort level.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=318 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Ora Calibra® Drop Comfort Scale
Upon instillation on Day 1
3.5 score on a scale
Standard Deviation 2.75
3.5 score on a scale
Standard Deviation 2.79
Ora Calibra® Drop Comfort Scale
1 minute post-instillation on Day 1
2.5 score on a scale
Standard Deviation 2.32
2.5 score on a scale
Standard Deviation 2.12
Ora Calibra® Drop Comfort Scale
2 minutes post-instillation on Day 1
2.1 score on a scale
Standard Deviation 2.19
2.0 score on a scale
Standard Deviation 2.02

SECONDARY outcome

Timeframe: From Day -14 to Day 56

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of overall ocular discomfort twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=310 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=311 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Day -14 - Day -1 (Baseline) Daily Average
2.7 score on a scale
Standard Deviation 0.96
2.7 score on a scale
Standard Deviation 1.02
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Day 1 - Day 7, Daily Average Change from Baseline
-0.1 score on a scale
Standard Deviation 0.49
-0.1 score on a scale
Standard Deviation 0.52
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Day 8 - Day 14, Daily Average Change from Baseline
-0.2 score on a scale
Standard Deviation 0.56
-0.1 score on a scale
Standard Deviation 0.58
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Day 15 - Day 21, Daily Average Change from Baseline
-0.2 score on a scale
Standard Deviation 0.66
-0.2 score on a scale
Standard Deviation 0.70
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Day 22 - Day 28, Daily Average Change from Baseline
-0.3 score on a scale
Standard Deviation 0.71
-0.3 score on a scale
Standard Deviation 0.79
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Day 29 - Day 35, Daily Average Change from Baseline
-0.3 score on a scale
Standard Deviation 0.76
-0.2 score on a scale
Standard Deviation 0.80
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Day 36 - Day 42, Daily Average Change from Baseline
-0.3 score on a scale
Standard Deviation 0.77
-0.3 score on a scale
Standard Deviation 0.85
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Day 43 - Day 49, Daily Average Change from Baseline
-0.3 score on a scale
Standard Deviation 0.83
-0.4 score on a scale
Standard Deviation 0.89
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Day 50 - Day 56, Daily Average Change from Baseline
-0.3 score on a scale
Standard Deviation 0.83
-0.4 score on a scale
Standard Deviation 0.93

SECONDARY outcome

Timeframe: From Day -14 to Day 56

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of burning twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=316 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=318 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Day -14 - Day -1 (Baseline) Daily Average
1.9 score on a scale
Standard Deviation 1.21
1.8 score on a scale
Standard Deviation 1.21
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Day 1 - Day 7, Daily Average Change from Baseline
-0.1 score on a scale
Standard Deviation 0.44
-0.1 score on a scale
Standard Deviation 0.53
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Day 8 - Day 14, Daily Average Change from Baseline
-0.2 score on a scale
Standard Deviation 0.58
-0.2 score on a scale
Standard Deviation 0.60
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Day 15 - Day 21, Daily Average Change from Baseline
-0.2 score on a scale
Standard Deviation 0.63
-0.2 score on a scale
Standard Deviation 0.69
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Day 22 - Day 28, Daily Average Change from Baseline
-0.3 score on a scale
Standard Deviation 0.69
-0.3 score on a scale
Standard Deviation 0.75
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Day 29 - Day 35, Daily Average Change from Baseline
-0.3 score on a scale
Standard Deviation 0.71
-0.3 score on a scale
Standard Deviation 0.80
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Day 36 - Day 42, Daily Average Change from Baseline
-0.3 score on a scale
Standard Deviation 0.73
-0.3 score on a scale
Standard Deviation 0.83
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Day 43 - Day 49, Daily Average Change from Baseline
-0.3 score on a scale
Standard Deviation 0.78
-0.3 score on a scale
Standard Deviation 0.87
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Day 50 - Day 56, Daily Average Change from Baseline
-0.3 score on a scale
Standard Deviation 0.82
-0.4 score on a scale
Standard Deviation 0.92

SECONDARY outcome

Timeframe: From Day -14 to Day 56

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of dryness twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=316 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=318 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Day -14 - Day -1 (Baseline) Daily Average
3.0 score on a scale
Standard Deviation 0.94
2.9 score on a scale
Standard Deviation 0.97
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Day 1 - Day 7, Daily Average Change from Baseline
-0.1 score on a scale
Standard Deviation 0.47
-0.1 score on a scale
Standard Deviation 0.46
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Day 8 - Day 14, Daily Average Change from Baseline
-0.3 score on a scale
Standard Deviation 0.58
-0.2 score on a scale
Standard Deviation 0.57
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Day 15 - Day 21, Daily Average Change from Baseline
-0.3 score on a scale
Standard Deviation 0.66
-0.3 score on a scale
Standard Deviation 0.68
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Day 22 - Day 28, Daily Average Change from Baseline
-0.4 score on a scale
Standard Deviation 0.74
-0.4 score on a scale
Standard Deviation 0.74
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Day 29 - Day 35, Daily Average Change from Baseline
-0.4 score on a scale
Standard Deviation 0.78
-0.3 score on a scale
Standard Deviation 0.77
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Day 36 - Day 42, Daily Average Change from Baseline
-0.5 score on a scale
Standard Deviation 0.81
-0.4 score on a scale
Standard Deviation 0.84
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Day 43 - Day 49, Daily Average Change from Baseline
-0.5 score on a scale
Standard Deviation 0.88
-0.5 score on a scale
Standard Deviation 0.88
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Day 50 - Day 56, Daily Average Change from Baseline
-0.5 score on a scale
Standard Deviation 0.88
-0.5 score on a scale
Standard Deviation 0.93

SECONDARY outcome

Timeframe: From Day -14 to Day 56

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of grittiness twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=316 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=318 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Day -14 - Day -1 (Baseline) Daily Average
2.1 score on a scale
Standard Deviation 1.26
2.0 score on a scale
Standard Deviation 1.27
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Day 1 - Day 7, Daily Average Change from Baseline
-0.2 score on a scale
Standard Deviation 0.49
-0.1 score on a scale
Standard Deviation 0.57
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Day 8 - Day 14, Daily Average Change from Baseline
-0.3 score on a scale
Standard Deviation 0.64
-0.2 score on a scale
Standard Deviation 0.64
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Day 15 - Day 21, Daily Average Change from Baseline
-0.3 score on a scale
Standard Deviation 0.69
-0.2 score on a scale
Standard Deviation 0.71
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Day 22 - Day 28, Daily Average Change from Baseline
-0.4 score on a scale
Standard Deviation 0.75
-0.3 score on a scale
Standard Deviation 0.77
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Day 29 - Day 35, Daily Average Change from Baseline
-0.4 score on a scale
Standard Deviation 0.77
-0.3 score on a scale
Standard Deviation 0.79
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Day 36 - Day 42, Daily Average Change from Baseline
-0.4 score on a scale
Standard Deviation 0.76
-0.3 score on a scale
Standard Deviation 0.85
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Day 43 - Day 49, Daily Average Change from Baseline
-0.4 score on a scale
Standard Deviation 0.84
-0.4 score on a scale
Standard Deviation 0.88
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Day 50 - Day 56, Daily Average Change from Baseline
-0.4 score on a scale
Standard Deviation 0.85
-0.4 score on a scale
Standard Deviation 0.93

SECONDARY outcome

Timeframe: From Day -14 to Day 56

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of stinging twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

Outcome measures

Outcome measures
Measure
0.25% HL036 Ophthalmic Solution
n=316 Participants
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=318 Participants
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Day -14 - Day -1 (Baseline) Daily Average
1.7 score on a scale
Standard Deviation 1.25
1.7 score on a scale
Standard Deviation 1.23
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Day 1 - Day 7, Daily Average Change from Baseline
-0.1 score on a scale
Standard Deviation 0.48
-0.1 score on a scale
Standard Deviation 0.53
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Day 8 - Day 14, Daily Average Change from Baseline
-0.3 score on a scale
Standard Deviation 0.62
-0.2 score on a scale
Standard Deviation 0.60
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Day 15 - Day 21, Daily Average Change from Baseline
-0.3 score on a scale
Standard Deviation 0.68
-0.3 score on a scale
Standard Deviation 0.65
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Day 22 - Day 28, Daily Average Change from Baseline
-0.4 score on a scale
Standard Deviation 0.72
-0.3 score on a scale
Standard Deviation 0.70
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Day 29 - Day 35, Daily Average Change from Baseline
-0.4 score on a scale
Standard Deviation 0.74
-0.3 score on a scale
Standard Deviation 0.73
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Day 36 - Day 42, Daily Average Change from Baseline
-0.4 score on a scale
Standard Deviation 0.76
-0.3 score on a scale
Standard Deviation 0.79
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Day 43 - Day 49, Daily Average Change from Baseline
-0.4 score on a scale
Standard Deviation 0.79
-0.4 score on a scale
Standard Deviation 0.82
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Day 50 - Day 56, Daily Average Change from Baseline
-0.4 score on a scale
Standard Deviation 0.84
-0.4 score on a scale
Standard Deviation 0.86

Adverse Events

0.25% HL036 Ophthalmic Solution

Serious events: 5 serious events
Other events: 78 other events
Deaths: 1 deaths

Placebo

Serious events: 4 serious events
Other events: 76 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
0.25% HL036 Ophthalmic Solution
n=318 participants at risk
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 participants at risk
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Infections and infestations
Appendiceal abscess
0.31%
1/318 • Number of events 1 • Baseline up to 8 weeks
0.00%
0/319 • Baseline up to 8 weeks
Infections and infestations
Appendicitis
0.31%
1/318 • Number of events 1 • Baseline up to 8 weeks
0.00%
0/319 • Baseline up to 8 weeks
Infections and infestations
Diverticulitis
0.00%
0/318 • Baseline up to 8 weeks
0.31%
1/319 • Number of events 1 • Baseline up to 8 weeks
Infections and infestations
Osteomyelitis
0.00%
0/318 • Baseline up to 8 weeks
0.31%
1/319 • Number of events 1 • Baseline up to 8 weeks
Musculoskeletal and connective tissue disorders
Intervertebral disc protrusion
0.31%
1/318 • Number of events 1 • Baseline up to 8 weeks
0.00%
0/319 • Baseline up to 8 weeks
Musculoskeletal and connective tissue disorders
Osteoarthritis
0.00%
0/318 • Baseline up to 8 weeks
0.31%
1/319 • Number of events 1 • Baseline up to 8 weeks
Cardiac disorders
Acute myocardial infarction
0.00%
0/318 • Baseline up to 8 weeks
0.31%
1/319 • Number of events 1 • Baseline up to 8 weeks
Cardiac disorders
Ventricular fibrillation
0.00%
0/318 • Baseline up to 8 weeks
0.31%
1/319 • Number of events 1 • Baseline up to 8 weeks
Gastrointestinal disorders
Gastrointestinal haemorrhage
0.00%
0/318 • Baseline up to 8 weeks
0.31%
1/319 • Number of events 1 • Baseline up to 8 weeks
Investigations
Blood pressure increased
0.31%
1/318 • Number of events 1 • Baseline up to 8 weeks
0.00%
0/319 • Baseline up to 8 weeks
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage IV
0.31%
1/318 • Number of events 1 • Baseline up to 8 weeks
0.00%
0/319 • Baseline up to 8 weeks
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
0.31%
1/318 • Number of events 1 • Baseline up to 8 weeks
0.00%
0/319 • Baseline up to 8 weeks
Vascular disorders
Peripheral arterial occlusive disease
0.00%
0/318 • Baseline up to 8 weeks
0.31%
1/319 • Number of events 1 • Baseline up to 8 weeks
Infections and infestations
Peritonitis
0.31%
1/318 • Number of events 1 • Baseline up to 8 weeks
0.00%
0/319 • Baseline up to 8 weeks

Other adverse events

Other adverse events
Measure
0.25% HL036 Ophthalmic Solution
n=318 participants at risk
Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=319 participants at risk
Participants sefl-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
General disorders
Instillation site pain
19.5%
62/318 • Baseline up to 8 weeks
18.2%
58/319 • Baseline up to 8 weeks
Eye disorders
Visual acuity reduced
5.0%
16/318 • Baseline up to 8 weeks
5.6%
18/319 • Baseline up to 8 weeks

Additional Information

Project Manager

Hanall Biopharma

Phone: 82-222041763

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place